Toggle Main Menu Toggle Search

Open Access padlockePrints

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

Lookup NU author(s): Professor Alan Boddy, Professor Ruth Plummer, Julieann Sludden, Melanie Griffin, Dr Mark Verrill, Professor Alan Calvert


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and toxicities associated with administration of paclitaxel poliglumex (PPX, XYOTAX, Cell Therapeutics, Inc., Bresso, Italy) given on either 3-weekly or 2-weekly schedule. Experimental Design: Nineteen patients were investigated on the 3-weekly phase la study and 11 patients on the 2-weekly phase lb study. Dose escalation starting with 100% increments and one patient per dose level was modulated in accordance with the observed toxicities. Conjugated and unconjugated paclitaxel were measured in plasma. Results: Dose-limiting toxicity of neutropenia was encountered at 266 mg/m2 (paclitaxel equivalents) in phase la and the maximum tolerated dose was 233 mg/m2. Neuropathy was dose-limiting in phase lb with a maximum tolerated dose of 177 mg/m 2. Pharmacokinetic investigations indicated a prolonged half-life of >100 hours for conjugated taxanes. Plasma concentrations of unconjugated paclitaxel were similar to those following administration of an equivalent dose of Taxol. Two partial responses were observed, one in a patient with mesothelioma at 177 mg/m2 in phase la and one in a patient with gastric carcinoma at 175 mg/m2 in phase lb. Conclusion: PPX is a water-soluble paclitaxel-polymer conjugate with a prolonged half-life and limited volume of distribution. Dose-limiting toxicities were neutropenia and neuropathy. PPX showed activity in this patient population. © 2005 American Association for Cancer Research.

Publication metadata

Author(s): Boddy AV, Plummer ER, Todd R, Sludden J, Griffin MJ, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 2005

Volume: 11

Issue: 21

Pages: 7834-7840

Print publication date: 01/11/2005

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265


DOI: 10.1158/1078-0432.CCR-05-0803

PubMed id: 16278406


Altmetrics provided by Altmetric